[go: up one dir, main page]

WO2009071905A3 - Utilisation d'hydroxocobalamine et de glutathionylcobalamine en tant que régulateurs/agents promoteurs sélectifs de synthases d'oxyde nitrique inductibles et constitutives - Google Patents

Utilisation d'hydroxocobalamine et de glutathionylcobalamine en tant que régulateurs/agents promoteurs sélectifs de synthases d'oxyde nitrique inductibles et constitutives Download PDF

Info

Publication number
WO2009071905A3
WO2009071905A3 PCT/GB2008/004023 GB2008004023W WO2009071905A3 WO 2009071905 A3 WO2009071905 A3 WO 2009071905A3 GB 2008004023 W GB2008004023 W GB 2008004023W WO 2009071905 A3 WO2009071905 A3 WO 2009071905A3
Authority
WO
WIPO (PCT)
Prior art keywords
thiolatocobalamins
inducible
regulators
nitric oxide
oxide synthases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2008/004023
Other languages
English (en)
Other versions
WO2009071905A2 (fr
Inventor
Carmen Wheatley
Mauro Perretti
Acquisto Fulvio D
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Queen Mary University of London
Original Assignee
Queen Mary and Westfiled College University of London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Queen Mary and Westfiled College University of London filed Critical Queen Mary and Westfiled College University of London
Publication of WO2009071905A2 publication Critical patent/WO2009071905A2/fr
Publication of WO2009071905A3 publication Critical patent/WO2009071905A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des procédés de traitement et les utilisations de composés de thiolatocobalamines pour des maladies caractérisées par une dépression, un dysfonctionnement ou un dérèglement lié aux NOS, par exemple l'inflammation, la phase inflammatoire de la réponse immune, un syndrome de réponse inflammatoire systémique (SIRS)/une septicémie/un choc septique, traumatique, anaphylactique, une maladie bactérienne, virale ou parasitaire, le cancer, un traumatisme médullaire ou une maladie cardiovasculaire.
PCT/GB2008/004023 2007-12-07 2008-12-05 Utilisation d'hydroxocobalamine et de glutathionylcobalamine en tant que régulateurs/agents promoteurs sélectifs de synthases d'oxyde nitrique inductibles et constitutives Ceased WO2009071905A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0723972.6A GB0723972D0 (en) 2007-12-07 2007-12-07 Use of vitamin B12
GB0723972.6 2007-12-07

Publications (2)

Publication Number Publication Date
WO2009071905A2 WO2009071905A2 (fr) 2009-06-11
WO2009071905A3 true WO2009071905A3 (fr) 2009-08-20

Family

ID=39016338

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2008/004023 Ceased WO2009071905A2 (fr) 2007-12-07 2008-12-05 Utilisation d'hydroxocobalamine et de glutathionylcobalamine en tant que régulateurs/agents promoteurs sélectifs de synthases d'oxyde nitrique inductibles et constitutives

Country Status (2)

Country Link
GB (1) GB0723972D0 (fr)
WO (1) WO2009071905A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102684069B1 (ko) * 2017-12-21 2024-07-12 오사카 유니버시티 신경계 질환 치료제

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002087593A1 (fr) * 2001-04-25 2002-11-07 Cobalz Limited Methode de traitement ou de prevention d'une carence fonctionnelle en vitamine b12 chez un individu, et compositions medicales utilisees dans cette methode
WO2002100429A1 (fr) * 2001-06-11 2002-12-19 Transition Therapeutics Inc. Polytherapies a base de vitamine b12 et d'interferon destinees au traitement des affections virales, proliferantes et inflammatoires
US20030017135A1 (en) * 2001-07-17 2003-01-23 Cruz Tony F. Pharmaceutical compositions comprising vitamin B12 and interferon for treating multiple sclerosis
WO2007070983A1 (fr) * 2005-12-22 2007-06-28 Apollo Life Sciences Limited Livraison transdermale d'agents pharmaceutiques

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002087593A1 (fr) * 2001-04-25 2002-11-07 Cobalz Limited Methode de traitement ou de prevention d'une carence fonctionnelle en vitamine b12 chez un individu, et compositions medicales utilisees dans cette methode
WO2002100429A1 (fr) * 2001-06-11 2002-12-19 Transition Therapeutics Inc. Polytherapies a base de vitamine b12 et d'interferon destinees au traitement des affections virales, proliferantes et inflammatoires
US20030017135A1 (en) * 2001-07-17 2003-01-23 Cruz Tony F. Pharmaceutical compositions comprising vitamin B12 and interferon for treating multiple sclerosis
WO2007070983A1 (fr) * 2005-12-22 2007-06-28 Apollo Life Sciences Limited Livraison transdermale d'agents pharmaceutiques

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; February 2007 (2007-02-01), WHEATLEY CARMEN: "The return of the Scarlet Pimpernel: cobalamin in inflammation II - cobalamins can both selectively promote all three nitric oxide synthases (NOS), particularly iNOS and eNOS, and, as needed, selectively inhibit iNOS and nNOS", XP002515780, Database accession no. PREV200800207481 *
JOURNAL OF NUTRITIONAL & ENVIRONMENTAL MEDICINE (ABINGDON), vol. 16, no. 1-4, February 2007 (2007-02-01), pages 181 - 211, ISSN: 1359-0847 *
WHEATLEY CARMEN: "Cobalamin in inflammation III - glutathionylcobalamin and methylcobalamin/adenosylcobalamin coenzymes: the sword in the stone? How cobalamin may directly regulate the nitric oxide synthases", JOURNAL OF NUTRITIONAL & ENVIRONMENTAL MEDICINE (ABINGDON), vol. 16, no. 1-4, February 2007 (2007-02-01), pages 212 - 226, XP009112273, ISSN: 1359-0847 *
WHEATLEY ET AL: "A scarlet pimpernel for the resolution of inflammation? The role of supra-therapeutic doses of cobalamin, in the treatment of systemic inflammatory response syndrome (SIRS), sepsis, severe sepsis, and septic or traumatic shock", MEDICAL HYPOTHESES, EDEN PRESS, PENRITH, US, vol. 67, no. 1, 1 January 2006 (2006-01-01), pages 124 - 142, XP005397024, ISSN: 0306-9877 *

Also Published As

Publication number Publication date
GB0723972D0 (en) 2008-01-23
WO2009071905A2 (fr) 2009-06-11

Similar Documents

Publication Publication Date Title
PH12015500248A1 (en) Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
WO2010032059A3 (fr) Agents de liaison ciblés dirigés sur cd105 et leurs utilisations
WO2009036175A3 (fr) Inhibiteur de f1f0-atpase et procédés associés
WO2007075869A3 (fr) Composes heteroaryles bicycliques
WO2009052431A3 (fr) Agents de liaison au cd19 et utilisations de ceux-ci
WO2007106769A3 (fr) Anticorps se liant à la fois avec il-17a et il-17f et procédés d'utilisation
MY177564A (en) Anti-nr10 antibody and use thereof
WO2009026117A3 (fr) Nouveaux composés
WO2009013543A3 (fr) Agents de liaisons ciblés dirigés vers kdr, et utilisations de ceux-ci - 035
WO2009052081A3 (fr) Anticorps se liant à l'il-4 et/ou à l'il-3 et leurs utilisations
WO2009070243A3 (fr) Agents et épitopes de liaison à wise
WO2010151799A3 (fr) Composés de modulation des protéines de liaison à l'arn et applications associées
WO2009128963A3 (fr) Anticorps monoclonaux humains à neutralisation croisée dirigés contre sars-cov et procédés d'utilisation de ces derniers
WO2007084868A3 (fr) Traitement d'une inflammation et de troubles associes par l'activation de la reponse upr (proteine depliee)
WO2008100805A3 (fr) Anticorps anti-robo4 et utilisations de ceux-ci
WO2008070344A3 (fr) Compositions et procédés permettant une liaison sphingosine-1-phosphate
WO2008097439A3 (fr) Anticorps contre des maladies auto-immunes pour traiter le pemphigus
WO2008060705A3 (fr) Anticorps anti-dll4 et leurs procédés d'utilisation
WO2009071696A3 (fr) Molécules d'anticorps humanisés spécifiques pour il-31
WO2008029096A3 (fr) Composés d'activation de p53
WO2008133684A8 (fr) Anticorps qui se lient à la fois à il-17a et il-17f et leurs procédés d'utilisation
WO2007021937A3 (fr) Derives heterocycliques insatures
WO2007106915A8 (fr) Anticorps à efgl 7 et leurs procédés d'utilisation
WO2007133562A3 (fr) Composés d'hétéroaryle monocyclique
WO2008099178A3 (fr) ÉLÉMENTS DE LIAISON POUR MOLÉCULES IgE

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08856448

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08856448

Country of ref document: EP

Kind code of ref document: A2